GSK Plc has confirmed its sales target of £40 billion for 2031 following a second quarter of higher turnover for its specialty medicines and vaccines. The forecast is based on the sales trajectory of recently launched products as well as new ones poised for market entry. For 2025 the company expects sales to increase towards the top end of a 3% to 5% range.
US-based MapLight Therapeutics Inc has raised $372.5 million in a Series D financing to advance its portfolio of drugs for central nervous system disorders. Announced on 28 July, the deal was co-led by Forbion and Life Sciences at Goldman Sachs Alternatives and stands out as one of the larger private financings of the year. It will support ongoing Phase 2 clinical trials in schizophrenia and Alzheimer’s disease psychosis, a condition that is estimated to affect 40% of people with the disease.
Abivax SA has secured new financing of up to $747.5 million from a public offering of American Depositary Shares (ADSs) in the wake of two successful Phase 3 trial results for a small molecule drug for ulcerative colitis. Both trials achieved clinical remissions for a significant number of patients. The offering was initially announced on 23 July with the intention of raising $400 million. But after the trial results were reported, the company’s shares experienced a five-fold increase in value.
Obesity Review
New approaches drive obesity R&D
Clinical Research
The inflammasome as a target for obesity
Research News
Understanding human ageing
Oncology Review
New cancer drugs reset the standard of care
Regulation and Policy
Regulators explore alternatives to animal studies
Company News
Lilly partners with Camurus
Novo seeks small molecules
Cell and Gene Therapy
Funding for SpliceBio
